Exploring the conformational dynamics of PD1 in complex with different ligands: What we can learn for designing novel PD1 signaling blockers?. Issue 2 (11th September 2020)

• Record Type: Journal Article
• Authors: Ponce, Luis F.; García‐Martínez, Karina; León, Kalet; Valiente, Pedro A.
• Is Part Of: Proteins. Volume 89:Issue 2(2021)
• Page Start: 141
• Page End: 148
• Publication Date: 2020-09-11
• Subjects: conformational selection -- molecular dynamics -- PD1 -- principal component analysis; Proteins -- Periodicals; Proteins -- Periodicals; 572.6
• DOI: 10.1002/prot.26000
• Languages: English
• ISSNs: 0887-3585

Abstract

Abstract: Activation of T cells triggers the expression of regulatory molecules like the programmed cell death 1 (PD1) protein. The association of PD1 with the natural ligands PDL1 and PDL2 induces an inhibitory signal that prevents T cells from proliferating and exerting effector functions. However, little is known about how the binding of the ligands induce the PD1 inhibitory signal over T cells effector functions. Here, we explore the dynamics of PD1 free, and in complex with different PDL1 variants as well as the therapeutic antibodies nivolumab and pembrolizumab in order to assess the conformational changes in PD1 related to the signaling process. Our simulations suggest a pre‐conformational selection mechanism for the binding of the different PDL1 variants, while an induced‐fit model fits better for the molecular recognition process of the therapeutic antibodies. A deep analysis of the changes on PD1 movement upon the binding to different ligands revealed that as larger is the difference in the conformation adopted by loop C′D with respect to the complex with PDL1 is higher the ligand ability to reduce the PD1 inhibitory signaling. This behavior suggests that targeting specific conformations of this loop can be useful for designing therapies able to recover T cells effector functions.